DWP16001 is currently in a phase 2 clinical trial as a novel anti-diabetes drug for the treatment of type 2 diabetes by selective inhibition of sodium-glucose cotransporter 2. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.